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ABSTRACT The lipid transport protein, apolipoprotein E
(apoE), is expressed in many peripheral tissues in vivo including
the adrenal gland and testes. To investigate the role of apoE in
adrenal cholesterol homeostasis, we have expressed a human
apoE genomic clone in the Y1 mouse adrenocortical cell line.
Y1 cells do not express endogenous apoE mRNA or protein.
Expression of apoE in Y1 cells resulted in a dramatic decrease
in basal steroidogenesis; secretion of fluorogenic steroid was
reduced 7- to >100-fold relative to Y1 parent cells. Addition of
5-cholesten-3/3,25-diol failed to overcome the suppression of
steroidogenesis in these cells. Cholesterol esterification under
basal conditions, as measured by the production of cholesteryl
[14C]oleate, was similar in the Y1 parent and the apoE-
transfected cell lines. Upon incubation with adrenocorticotro-
pin or dibutyryl cAMP, production of cholesteryl [14C]oleate
decreased 5-fold in the Y1 parent cells but was unchanged in the
apoE-transfected cell lines. These results suggest that apoE
may be an important modulator of cholesterol utilization and
steroidogenesis in adrenal cells.
The lipid transport protein, apolipoprotein E (apoE), is an
important modulator of cholesterol homeostasis in vivo. An
integral component of very low density lipoproteins
(VLDLs), chylomicron remnants, and some subclasses of
high density lipoprotein, apoE functions as a ligand for the
low density lipoprotein (LDL) receptor on peripheral cells
and the LDL and remnant receptor on hepatocytes (1-4).
Lipoprotein-supplied cholesterol is used for membrane syn-
thesis in all cells and for hormone synthesis in steroidogenic
cells. Unlike most apolipoproteins that are synthesized solely
in the liver and intestine, apoE is synthesized in a number of
peripheral tissues (5). The function of apoE in peripheral
tissues is unclear. One hypothesis is that apoE is involved in
transporting cholesterol from peripheral tissues to the liver
for clearance, a process referred to as "reverse cholesterol
transport" (5). apoE may also function in an autocrine or
paracrine fashion to facilitate the local redistribution of
cholesterol among cells within a tissue (5-7). apoE mRNA
and protein synthesis are regulated by cell cholesterol con-
tent in macrophages (8, 9) and by changes in cholesterol
biosynthesis in rat ovarian granulosa cells (10).
apoE is particularly abundant in steroidogenic tissues. In
human or monkey adrenal tissue apoE is synthesized at a
relative rate similar to, or greater than, that seen in the liver
(5, 6). Adrenocortical cells in vivo and cultured adrenal cells
in vitro synthesize steroid hormones from cholesterol in
response to adrenocorticotropin (ACTH) stimulation. In vivo
studies demonstrate a direct correlation between rat adrenal
apoE expression and total cell cholesterol and an inverse
relationship between apoE expression and adrenal ste-
roidogenesis (11).
The mouse Y1 adrenocortical cell line is functionally
similar to adrenal cells in vivo (12, 13), although Y1 cells do
not express detectable levels of apoE mRNA or protein. To
investigate the relationship between adrenal apoE expression
and cholesterol utilization we have transfected Y1 cells with
a human genomic apoE expression vector. We report here
that both basal and ACTH-stimulated steroidogenesis is
dramatically reduced in the Y1 cell clones that express
human apoE. These results provide evidence that apoE may
play a role in regulating cholesterol utilization in adrenal cells
and possibly other steroidogenic tissues.
MATERIALS AND METHODS
Cell Culture. The Y1 adrenal cell line was obtained from
the American Type Culture Collection and maintained in
Ham's F-10 medium supplemented with penicillin (100 units
per ml), streptomycin sulfate (100 ,ug/ml), 2mM L-glutamine,
12.5% (vol/vol) heat-inactivated horse serum, and 2.5%
(vol/vol) heat-inactivated fetal calfserum (FCS) (medium A).
Ham's F-10 was obtained from Sigma; all additional cell
culture reagents were obtained from GIBCO. For some
experiments cells were cultured in medium B, which con-
tained 5% horse serum and 2.5% FCS, or medium C, which
contained 2% lipoprotein-poor FCS. Porcine ACTH (Parke-
Davis), NM,02-dibutyryladenosine 3',5'-cyclic monophos-
phate [(Bt)2cAMP] (Sigma) and 5-cholesten-3,3,25diol (25-
OH-cholesterol) (Steraloids, Wilton, NH) were added to
cultures as described in the figure legends.
Transfection. The human genomic apoE expression vector
(pFE) was constructed from the plasmids pJS1 and pJS15,
provided by J. Smith and J. Breslow (The Rockefeller Uni-
versity). The 2-kilobase (kb) Nar I-EcoRI fragment from
pJS1 was inserted into vector pT7/T3a-18 (BRL) to yield
pFE1. The 2-kb EcoRI fragment from pJS15 was then in-
serted into pFE1 at the unique EcoRI site to yield pFE. pFE
contains the entire genomic sequence of human apoE, in-
cluding :500 nucleotides (nt) 5' of the transcription start site
and 628 nt 3' of the polyadenylylation site. Calcium phos-
phate-mediated gene transfer was essentially as described
(14). Y1 cells were cotransfected with 2 ,g of pSV2neo and
18 ,g of pFE or pUC8; transfected cells were selected in
medium A containing G418 sulfate (active form) at 200 ,tg/ml
(Geneticin, GIBCO). Survivors were cloned and maintained
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in medium A containing G418 sulfate (active form) at 100
tKg/ml.
Quantification of apoE mRNA. For RNA blot analysis, 10
gg of total RNA was separated on a 1.2% agarose gel
containing 2.2 M formaldehyde, transferred to Nytran (Schlei-
cher& Schuell), crosslinked with UV light (Stratalinker), and
hybridized to a single-stranded human apoE cDNA probe
labeled with [a-32P]dCTP (Amersham; 800 Ci/mmol; 1 Ci =
37 GBq). As control for quantitative RNA recovery, the same
blot was stripped by boiling in distilled H20 for 15 min and
reprobed with a rat glyceraldehyde phosphate dehydroge-
nase cDNA probe (from K. Marcu, State University ofNew
York at Stony Brook) prepared by random priming with
[a-32P]dCTP (Amersham; 800 Ci/mmol). DNA-excess solu-
tion hybridization assays for human apoE mRNA (15) and
mouse apoE mRNA (16) were done as described.
Metabolic Labeling and Immunoprecipitation. Cells were
incubated for 14 hr in 50o Ham's F-10 medium/50%o me-
thionine-free Dulbecco's modified Eagle's medium supple-
mented with [35S]methionine (50 ACi/ml; >800 Ci/mmol;
Amersham), 5% dialyzed horse serum, and 2.5% dialyzed
FCS. Culture medium was adjusted to aprotinin and leupep-
tin (Sigma) each at 12 ttg/ml, centrifuged to remove cells, and
analyzed by using a double-antibody procedure (17). Excess
goat anti-human apoE antisera (Calbiochem) was used as
primary antibody, and sheep anti-goat gamma globulin (Cap-
pel Laboratories) was used as secondary antibody. Control
immunoprecipitates contained normal goat serum as primary
antibody. Immunoprecipitates were resolved by NaDodSO4/
10% polyacrylamide gel electrophoresis followed by fluorog-
raphy (17). To quantify the radioactivity incorporated into
apoE protein, the apoE band was cut from the dried gel and
solubilized; radioactivity was counted by liquid scintillation
spectrometry (17).
Measurement of Secreted Steroids. Fluorogenic steroids
were measured as described (18) by using a modification of
the method of Kowal and Fiedler (19). Individual steroid
products were analyzed by HPLC on a reverse-phase C18
column. Products were separated isocratically with a mobile
phase of methanol/acetonitrile water (11:45:44) at a flow rate
of 1.1 ml/min (20). HPLC standards, obtained from Sigma,
were as follows: 18-hydroxy-11-deoxycorticosterone, corti-
costerone, 11-deoxycorticosterone, 20a-hydroxypregn-4-en-
3-one, and progesterone.
Cholesterol Esterification. [14C]Oleate (ICN; 57.4 ,tCi/
mmol) was bound to albumin as described (21). Cells were
cultured in the presence of [14C]oleate for 6 hr. Lipids were
extracted from labeled cells, and the amount of cholesteryl
[14C]oleate and [14C]triglycerides was determined after thin-
layer chromatography (21). [cholesteryl-1,2,6,7-3H(N)]-
Oleate (NEN; 82.9 Ci/nmol) was added to each sample to
determine recovery. After lipid extraction, cells were
scraped into 1.0 M NaOH for protein determination (22).
Miscellaneous. RNA was prepared by the guanidine iso-
thiocyanate/ethanol precipitation method (23). Cell protein
concentration was determined by the method of Lowry et al.
(22) by using bovine serum albumin (Sigma) as a standard.
Lipoprotein-poor FCS was prepared as described (21). Hu-
man [14C]apoE was prepared as described (24).
endogenous apoE mRNA was detected in either the Y1
parent or Y1-neo cell lines when assayed by DNA-excess
solution hybridization with a mouse cDNA probe (data not
shown). To screen clones for expression of human apoE
mRNA, total RNA was prepared from Y1 parent cells and 16
Y1-E cell lines and subjected to Northern blot analysis. Fig.
1 shows that the human apoE mRNA expressed by Y1-E
clonal cell lines is identical in size to apoE mRNA from the
human liver cell line HepG2. The transcription start site of
HepG2 apoE mRNA and the apoE mRNA expressed in the
Y1-E clones are also identical, as determined by primer
extension (data not shown). Human apoE mRNA was quan-
tified by DNA-excess solution hybridization by using a 221-nt
single-stranded probe, 160 nt of which are complementary to
human apoE mRNA. Previous work has shown that human
apoE mRNA completely protects the expected 160-nt probe
fragment from digestion by S1 nuclease (15). No hybridiza-
tion above the limit of detection (0.1 pg mRNA per ,g of
RNA) was seen with RNA from the Y1 parent or the Y1-neo
cell lines. Among Y1-E clones examined, expression varied
as much as 150-fold; representative values are shown in Table
1. Clone Y1-E15 expressed 0.8 pg of apoE mRNA per ug of
total RNA, a level considerably lower than that seen in the rat
adrenal gland in vivo (25). Clone Y1-E1 expressed 17 pg of
apoE mRNA per ,ug of total RNA, a level within the range
observed in rat adrenal gland in vivo (25) and comparable to
the apoE mRNA concentration of the human liver cell line,
HepG2 (22 pg per ug of total RNA) (26). The Y1-E12 cell
clone expressed the highest amount of apoE mRNA, 120 pg
of apoE mRNA per ,ug of total RNA. This level is similar to
that seen in rat hepatocytes (25) and is approximately twice
the maximal level seen in rat adrenal gland in vivo (11). No
apparent toxicity resulted from expression of human apoE at
this level; all Y1-E cell lines had growth rates similar to, or
faster than, the Y1 parent or Y1-neo cell lines (data not
shown). Secreted human apoE protein was detected by
immunoprecipitation of medium from cells incubated with
[35S]methionine. Fig. 2 shows that the goat anti-human apoE
antibody precipitated a protein from Y1-E1, Y1-E16, and
Y1-E12 culture media identical in molecular weight to apoE
precipitated from HepG2 culture medium. No apoE protein
was detected in culture medium from the Y1 parent cells (lane
6) or in control immunoprecipitations that used nonimmune
goat serum as the primary antibody (lane 1). The amount of
secreted apoE protein correlated approximately with the
mRNA content of the individual clonal lines analyzed. apoE
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RESULTS
Expression of Human apoE mRNA and Protein. Y1 cells
were transfected with pSV2neo plus the human genomic
apoE expression vector pFE. Individual colonies of G418
sulfate-resistant cells were isolated and expanded into cell
lines (Y1-E1-Y1-E16). As control for expression of the
neomycin-resistance gene, Y1 cells were cotransfected with
pSV2neo and pUC8. Approximately 200 G418-resistant
clones were pooled; this cell line is referred to as Y1-neo. No
18S- *% w, ,, _ _, _ 0 ,W O.
FIG. 1. Northern blot analysis of RNA from Y1 parent, Y1-E
clones, and HepG2 cells. (A) Blot is probed with human apoE cDNA.
(B) The same blot was stripped and reprobed with a rat glyceralde-
hyde phosphate dehydrogenase cDNA probe. Lanes: 1, Yb-El; 2,
Y1-E2; 3, Y1-E6; 4, Y1-E9; 5, Yb-Eli; 6, Yl-E12; 7, Yl-E14; 8,
Yl-E16; 9, Y1 parent; 10, HepG2.
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Table 1. Quantification of fluorogenic steroid production and
apoE mRNA
Fluorogenic steroid,
apoE mRNA, pg/mg of cell protein
Cell line pg/,ug of RNA Basal ACTH (Bt)2cAMP
Y1 <0.1 2.79 5.47 28.72
Y1-neo <0.1 3.08 NT 26.33
Y1-E1 17.2 <0.01 <0.01 <0.01
Y1-E12 120.0 0.11 0.14 0.28
Y1-E15 0.8 0.38 NT 10.00
Y1-E16 57.2 0.05 0.06 0.17
Cells were plated on day 1 in medium A. On day 3, medium was
replaced with medium B (basal conditions), medium B/10-7 M
ACTH or medium B/1 mM (Bt)2cAMP, as indicated. After an
additional 24 hr, culture medium was assayed for fluorogenic steroids
as described. apoE mRNA was assayed by hybridization in DNA-
excess solution with a mouse cDNA probe (Y1 and Yl-neo cells) or
a human cDNA probe (Y1-E cell lines). Numbers represent the
average of three or more measurements. Variation between mea-
surements was <10%6. NT, not tested.
by Yl-E1 cells, a level comparable to the human liver cell line
HepG2 (0.4%) and the human and monkey adrenal gland
(0.5-1.2%) (5, 6). Thus, apoE mRNA and protein levels in the
various Y1-E clones are within the range seen in liver and
adrenal cells in vivo (15, 25).
Analysis of Steroid Production in Y1-E Cells. As an indica-
tor of cholesterol utilization in the Y1-E cells, we measured
secreted steroids by using the fluorometric assay of Kowal
and Fiedler (19). Table 1 shows that human apoE expression
in Y1 cells dramatically decreased the secretion of fluoro-
genic steroids. Secretion of fluorogenic steroid under basal
conditions was reduced 7- to >100-fold in the Y1-E cell lines
compared with the Y1 parent or the Yl-neo cells. Although
basal steroidogenesis was suppressed in all Y1-E cell lines,
the cell line that expresses the lowest level of apoE mRNA,
Yl-E15, was the least affected. ACTH stimulated steroid
secretion by the Y1 parent cells 2-fold but had no effect on
steroid secretion by the Y1-E cell line examined. Conceiv-
ably, the lack ofACTH responsiveness in the Y1-E cell lines
could reflect the loss of ACTH receptors or a block in the
generation of the second messenger cAMP. To address these
possibilities Y1 cells were treated with the cAMP analog,
(Bt)2cAMP, a potent stimulator of steroidogenesis. Incuba-
tion with 1 mM (Bt)2cAMP increased secretion offluorogenic
steroid by Y1 parent and Yl-neo cells 8- to 10-fold (Table 1).
Steroid production by the Y1-E12 and Y1-E16 cell lines was




increased 2- to 4-fold under these conditions. Steroid secre-
tion by Yl-E15 cells was increased 26-fold by (Bt)2cAMP,
although this level of steroid production was still 3-fold lower
than that seen for Y1 parent cells under identical conditions.
ACTH or (Bt)2cAMP had no effect on apoE mRNA or protein
synthesis in the Y1-E cell lines (data not shown).
In rat ovarian theca/interstitial cells, exogenous apoE
alters the profile of secreted steroids by inhibiting the con-
version of progesterone to androgen (27). The major steroid
products of Y1 cells, 20a-dihydroprogesterone and 11,8-
hydroxy, 20a-dihydroprogesterone (12, 13) can be detected
with the fluorogenic steroid assay used above. To determine
whether the Y1-E cells produce nonfluorogenic steroids, we
analyzed culture medium from Y1 parent and Yl-E12 cells by
HPLC; Fig. 3 shows an HPLC profile ofculture medium from
these cells incubated for 24 hr in medium A/10-7 M ACTH.
At 254 nm two steroid products were detected in medium
from the Y1 parent cells. Peak A, the minor product, is
presumably 1 1,3-hydroxy, 20a-dihydroprogesterone,
whereas peak B has a retention time identical to the standard
20a-hydroxy-pregn-4-en-3-one (20a-dihydroprogesterone).
No steroids were detected in medium from the Y1-E12 cell
line, even when 10 times more medium was analyzed. Pro-
gesterone and its hydroxylated derivatives, but not preg-
nenolone, can be detected by absorption at 254 nm, whereas
pregnenolone can be detected at 210 nm. When media
extracts were separated by HPLC and analyzed at 210 nm, no
pregnenolone could be found in either the Y1 parent or
Yl-E12 cell lines. The absence of pregnenolone from the
parent line presumably reflects its rapid conversion to other
steroids. In contrast, the absence of pregnenolone and distal
steroid products from the Y1-E12 line appears to reflect
suppression at, or before, pregnenolone formation.
When available, Y1 cells preferentially utilize lipoprotein
cholesterol for steroid hormone synthesis (12). To determine
whether the Y1-E cell lines can utilize a nonlipoprotein
substrate for steroid production, ACTH-stimulated Y1 par-
ent, Y1-E1, and Y1-E12 cells were incubated in lipoprotein-
poor medium (medium C) with or without 25-OH-cholesterol
at 15 ,ug/ml. As seen in Fig. 4, the parent line effectively
converted 25-OH-cholesterol to fluorogenic steroid. In con-
trast, production of fluorogenic steroid from 25-OH-










FIG. 2. Immunoprecipitation of human apoE. Trichloroacetic
acid-precipitable counts (200,000) from each sample were analyzed.
Lanes: 1, nonimmune goat serum control; 2, HepG2; 3, Y1-E1; 4,





FIG. 3. HPLC analysis of se-
creted steroids. Y1 parent and
YlE12 Y1-E12 cells were grown to con-fluence in 60-mm dishes and
then incubated for 25 hr with
ACTH (10-7 M) in medium A.
The medium was then extracted
with 8 ml of methylene chloride,
and 5 ml of the extract was dried
under nitrogen and resolubilized
in 150 ,Al of methanol. Fifteen
microliters of the Y1 parent
product and 150 ,ul of the Y1-
Y1-P E12 product were analyzed by
HPLC. Standards are as fol-
lows: 1, 18-hydroxy-11-deoxy-
corticosterone; 2, corticoste-
5Stds rone; 3, 11-deoxycorticoste-
'K- rone; 4, 20a-hydroxy-pregn-4-
en-3-one; and 5, progesterone.
Biochemistry: Reyland et al.
















FIG. 4. Cells were plated on day 1 in medium B/ACTH (10-7 M).
On day 2, medium was replaced with medium C (open bars) or
medium C/25-OH-cholesterol at 15 ,Lg/ml (hatched bars) for an
additional 24 hr. Fluorogenic steroid in the culture medium was
measured as described.
Y1-E1 and Y1-E12 cell lines. These results suggest that the
suppression of steroidogenesis in the Y1-E cells may occur,
at least in part, at the mitochondrion level.
Incorporation of ['4C]Oleate into [14C]Cholsteryl Oleate.
To determine whether expression of apoE in Y1 cells alters
regulation of cholesterol esterification, we measured the
incorporation of [I4C]oleate into [14C]cholesteryl oleate in the
Y1 parent, the Y1-neo cells, and three Y1-E cell lines with
and without ACTH or (Bt)2cAMP stimulation. As seen in
Table 2, in the absence of ACTH, synthesis of [14C]-
cholesteryl oleate is comparable in all cell lines analyzed,
suggesting that apoE expression has no effect on esterifica-
tion rate. Incorporation of [14C]oleate into triglyceride was
equivalent in all cell lines tested, indicating that uptake of
['4C]oleate on albumin did not vary (data not shown). Upon
incubation with lo- M ACTH, incorporation of [14C]oleate
into [14C]cholesteryl oleate decreased 5- to 6-fold in the Y1
parent and Y1-neo cells, whereas no decrease was seen in the
three Y1-E cell lines examined. Similarly, stimulation of
steroidogenesis with (Bt)2cAMP reduced ['4C]cholesteryl
oleate formation in the Y1 parent and Yi-neo cell lines but
was without effect on Y1-E cell lines. These results suggest
that apoE may affect availability of cholesterol for steroid
synthesis.
DISCUSSION
The Y1 adrenal cell line has been used extensively as a model
for adrenal cholesterol metabolism and steroidogenesis in
vitro. Although functionally similar to adrenal cells in vivo,
Y1 cells do not have detectable levels of apoE mRNA or
Table 2. Cholesterol esterification
Production of ['4C]cholesteryl
oleate, pM/mg of cell protein
Cell line Basal ACTH (Bt)2cAMP
Y1 1683 546 331
Y1-neo 2982 563 367
Y1-E1 2765 3164 2957
Y1-E16 2145 2483 1860
Yl-E12 2511 2484 3251
Cells were plated on day 1 in medium A. On day 2 the medium was
replaced with medium B, and on day 3 the medium was again
replaced with medium B (basal conditions), medium B/1b-7 M
ACTH or medium B/1 mM (Bt)2cAMP, as indicated. After 24 hr,
medium was replaced with fresh medium containing [14C]oleate
bound to albumin (10,000 dpm/nmol) for 6 hr. Lipids were analyzed
as described. Numbers represent the average of two measurements;
variation between measurements was <15%.
protein, a normal product of adrenal glands and other ste-
roidogenic tissues. As a model to study the role of apoE in
adrenal cholesterol homeostasis, we introduced the human
genomic apoE gene into Y1 cells by transfection and isolated
Y1 clonal cell lines that express human apoE mRNA and
protein. Steroid hormone production was analyzed in these
cell lines to indicate cholesterol availability and utilization.
These experiments show that apoE expression in Y1 cells
markedly decreases both basal and ACTH- or (Bt)2cAMP-
stimulated steroidogenesis.
Although apoE is commonly thought of as a plasma cho-
lesterol transport protein, expression of apoE in many pe-
ripheral tissues suggests it may also function in cellular
cholesterol metabolism. In recent studies (11), treatment of
rats with ACTH or 4-aminopyrazolopyrimidine was shown to
decrease adrenal gland cholesterol and apoE mRNA'levels
and to increase plasma corticosterone levels. In contrast,
when rats were treated with dexamethasone to suppress
ACTH release, adrenal cholesterol content, apoE mRNA,
and apoE synthesis increased, whereas plasma corticoste-
rone decreased. Thus, in vivo, apoE expression correlates
positively with adrenal cholesterol content and negatively
with adrenal steroidogenesis. Taken together, the in vivo
results discussed above and the results presented here are
consistent with a role for apoE in regulating availability
and/or utilization of cholesterol for steroidogenesis.
Although steroidogenesis was suppressed in all Y1-E cell
lines examined, clone Y1-E15, which expresses the lowest
level of apoE mRNA, was the least affected. The level of
apoE mRNA expressed by this cell line is about 10-fold lower
than that seen in adrenal glands from rats treated with ACTH
or 4-aminopyrazolopyrimidine (11). If expression of physio-
logical levels of apoE mRNA completely suppresses ste-
roidogenesis in adrenal cells, how is it that adrenal cells in
vivo express apoE and produce steroid hormones? One
explanation is suggested by in situ hybridization studies in the
rat adrenal gland (M. Nicosia and D.L.W., unpublished
data). These studies show that apoE mRNA levels vary
substantially among cortical zones and are regulated in a
zone-specific manner in response to agents that alter ste-
roidogenesis. This cellular heterogeneity in apoE expression
may permit steroid production to occur in some cells that
express little or no apoE, whereas apoE expression is high in
other cells that are not producing steroids.
Secondly, down-regulation of apoE expression may be
required for steroidogenesis in adrenal cells. Although apoE
expression is decreased by ACTH and conditions-that deplete
adrenal cholesterol stores in the rat adrenal gland, apoE
mRNA and protein synthesis were not altered by ACTH or
(Bt)2cAMP in the Y1-E cell lines. Failure of apoE to be
down-regulated in the Y1-E cells may account for the ob-
served block in steroidogenesis. The lack of apoE regulation
in the Y1-E cells could be from the absence of regulatory
elements upstream or downstream of the genomic DNA used
in the expression vector.
ApoE may influence adrenal cholesterol homeostasis and
steroidogenesis in several ways. (i) Under basal conditions,
incorporation of [14C]oleate into [14C]cholesteryl oleate is
comparable in the Y1 parent, Yl-neo, and the three Y1-E cell
lines analyzed, even though fluorogenic steroid output varied
by >100-fold. When stimulated with ACTH or (Bt)2cAMP,
esterification is decreased in the Y1 parent and Y1-neo lines
but not in the Y1-E lines. One interpretation of this result is
that cholesterol transport from a precursor pool to the
mitochondrion is blocked in Y1-E cells, increasing the sub-
strate level for cholesterol esterification even with ACTH or
(Bt)2cAMP. Although the rate-limiting step in steroidogene-
sis is generally recognized to be cholesterol side-chain cleav-
age, the true rate-limiting step in steroidogenesis is probably
delivery of cholesterol to the inner mitochondrial membrane,
Proc. Natl. Acad. Sci. USA 88 (1991)
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the site of side-chain cleavage. A number of adrenal and liver
proteins have been identified that may be involved in intra-
cellular transport and mitochondrial cholesterol transport
(28-30).
(ii) A specific precursor pool of unesterified cholesterol
could be depleted in the Y1-E cells, perhaps because of
enhanced apoE-mediated cholesterol efflux from the cell
membrane. In the mouse Leydig cell line MA-10 Freeman
(31) has shown that the major pool of unesterified cholesterol
for steroidogenesis comes from the plasma membrane. If this
is the case, the alteration in Y1-E cells may be quite specific
for a distinct precursor pool because basal esterification rates
were not substantially different among examined Y1-E lines.
(iiH) Enhanced cholesterol esterification from a distinct
precursor pool, or decreased cholesteryl ester hydrolysis,
could reduce the unesterified cholesterol available for ste-
roidogenesis in the Y1-E cells. This result is consistent with
the sustained level of [14C]oleate incorporation into cho-
lesteryl ester in ACTH-treated Y1-E cells. Because we have
seen no major differences in cholesterol or cholesteryl ester
content between the Y1 parent, Y1-neo, and Y1-E cell lines
(data not shown), such enhanced esterification must reflect a
distinct and small cholesterol pool. Consistent with this
possibility is a recent report from Adelman and St. Clair (32)
showing that the addition of apoE to pigeon -VLDL,
normally devoid of apoE, stimulated cholesterol esterifica-
tion in mouse peritoneal macrophages with no change in
cholesteryl ester accumulation. Similarly, Kowal et al. (33)
showed that apoE-enriched rabbit p-VLDL stimulated cho-
lesterol esterification in human skin fibroblasts via the LDL-
receptor-related protein without detectable uptake of
/3-VLDL.
The results of experiments with 25-OH-cholesterol may
indicate alterations at other points in the steroidogenic path-
way in the Y1-E cells. The mitochondrial side-chain cleavage
enzyme can convert 25-OH-cholesterol to pregnenolone and
thereby stimulate the production offluorogenic steroids in Y1
cells. In contrast to the Y1 parent line, fluorogenic steroid
production from precursor 25-OH-cholesterol is reduced 41-
fold in the Y1-E1 cells and 4-fold in the Y1-E12 cells. These
results suggest a block or inhibition in Y1-E cells in choles-
terol side-chain cleavage activity or a restriction in the access
of the precursor to the mitochondrial enzyme. Whether this
effect is distinct from, or related to, the sustained level of
cholesterol esterification in Y1-E cells treated with ACTH or
(Bt)2cAMP is unclear. Previous studies have shown that
inhibition of cholesterol side-chain cleavage with aminoglut-
ethimide prevents the ACTH-stimulated decrease in choles-
terol esterification in Y1 cells (12). Thus, it is possible that the
primary block in the Y1-E cells is at the mitochondrion level.
Future experiments with isolated mitochondria should allow
uncoupling of cholesterol esterification, intracellular trans-
port, and mitochondrial events. Such studies will be neces-
sary to explore the mechanism by which apoE expression
suppresses steroidogenesis in Y1-E cells.
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